Abbott Laboratories ($ABT)

S.3304 mandates federal health program coverage for medical foods, creating a new guaranteed payment stream for manufacturers. Abbott Laboratories ($ABT), the dominant U.S. player in metabolic formulas through its Nutrition division, is the primary beneficiary. The bill is early-stage (referred to Finance Committee) but has bipartisan sponsorship and an identical House companion, providing moderate legislative momentum.

HR3826 expands Medicare coverage of diabetes self-management training, removing hour limits and testing virtual delivery. This structurally increases the diagnostically engaged Medicare beneficiary pool, directly benefiting CGM makers ($DXCM, $ABT) and insulin pump manufacturers ($MDT). The bill is early-stage but has a Senate companion and bipartisan sponsorship, and current stock prices for all three tickers are near 52-week lows, potentially discounting this structural catalyst.

HR7867 (Infant Formula Safety Modernization Act) directly burdens Abbott Laboratories ($ABT) with new mandatory testing and notification requirements at a time when $ABT is trading at $90.35, just $0.02 above its 52-week low. The bill is early-stage (referred to committee) but represents an additional regulatory headwind for the dominant US infant formula manufacturer already under FDA scrutiny after the 2022 plant shutdown.

HR5605, the Medical Device Nonvisual Accessibility Act, is in early committee stage with zero appropriation — a compliance mandate, not a spending bill. Home medical device makers face moderate retrofit costs but no immediate revenue impact. Market data shows medtech stocks already under broad 30-day pressure (-8% to -11%), and this bill adds a minor regulatory cost layer without near-term catalyst.

HR5343 would force Medicare to provide immediate 4-year coverage for FDA breakthrough devices, directly benefiting large medical device manufacturers by eliminating the current 1-3 year coverage lag. The bill passed the Ways & Means committee 37-3 but awaits floor action. Despite bearish recent price action (MDT -8.2%, ABT -11%, BDX -7.3% in 30 days), this bill represents a structural catalyst for device revenue acceleration.

HR1931, the Access to Pediatric Technologies Act, is an early-stage House bill that would require CMS to establish Medicare payment methodologies for qualifying pediatric devices and drugs upon manufacturer request. The bill is referred to two committees with no further action in over a year. It authorizes no direct funding - it creates a regulatory pathway. For med-tech and pharma companies with pediatric product lines (JNJ, ABT, MRK, PFE), the bill is directionally positive but procedurally distant from becoming law.